Pathophysiological Mechanisms Underlying Sarcopenia and Sarcopenic Obesity: A Systematic Review and Meta-Analysis of...

Sarcopenia and sarcopenic obesity (SO) represent significant age-related muscular disorders. Their specific biomarkers and pathophysiological mechanisms remain insufficiently elucidated. This study aims to identify differential and shared biomarkers between these conditions to reveal distinct pathophysiological processes, providing a foundation for precision diagnostics and targeted interventions. We conducted a systematic review and meta-analysis of studies examining biomarkers related to sarcopenia and SO in adults aged 45 and older. Electronic and manual searches were performed in PubMed, Web of Science, Cochrane Library, and Embase up to December 2024. The quality of each study was assessed using the National Institutes of Health Quality Assessment Tool. Meta-analysis was performed when at least three studies investigated the same biomarkers in frailty and sarcopenia, calculating the pooled effect size based on the standard mean difference using a random effects model. In total, 80 studies (64 on sarcopenia and 16 on SO) were included, encompassing 36,680 older adults (aged 45 and above) from 16 countries with varying levels of development. Participants were categorized based on their setting, age, and gender distribution. Sarcopenia is characterized by lower serum triglycerides and stable HDL/LDL ratios, while SO presents with higher triglycerides and disrupted cholesterol correlation, indicating distinct metabolic interactions. Analysis of inflammatory profiles revealed significantly elevated CRP levels in SO, with WBC as a specific marker, while TNF-α was associated with sarcopenia, suggesting a subtype-specific role of chronic inflammation. Vitamin D deficiency is prevalent in both conditions and may represent a potential therapeutic target. Subgroup analyses indicated an increased risk of muscle function decline in high-risk communities in developing regions, underscoring the urgent need for early intervention. A set of shared metabolic, hematologic, and inflammatory biomarkers was identified in sarcopenia and SO. These findings address a knowledge gap in biomarker research and highlight the distinct mechanisms involved in the development of both conditions. Developing biomarker-based diagnostic algorithms is essential for optimizing personalized treatment. Subgroup analyses have also identified high-risk populations, underscoring the need for early intervention.